Home Healthcare Pharmaceuticals Radioligand Therapy Market

Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
  7. North America Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
    6. U.S.
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    7. Canada
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
  8. Europe Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
    6. U.K.
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    7. Germany
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    8. France
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    9. Spain
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    10. Italy
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    11. Russia
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    12. Nordic
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    13. Benelux
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    14. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
  9. APAC Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
    6. China
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    7. Korea
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    8. Japan
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    9. India
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    10. Australia
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    11. Taiwan
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    12. South East Asia
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    13. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
  10. Middle East and Africa Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
    6. UAE
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    7. Turkey
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    8. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    9. South Africa
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    10. Egypt
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    11. Nigeria
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    12. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
  11. LATAM Radioligand Therapy Market Size Analysis
    1. Introduction
    2. Radioligand Therapy Market Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
      1. Lutetium-177 (Lu-177)
      2. Actinium-225 (Ac-225)
      3. Iodine-131 (I-131)
      4. Other Isotopes
    3. Radioligand Therapy Market Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
      1. Prostate-Specific Membrane Antigen
      2. Ki 67 Expression and Grading
      3. Cytochrome P450 17A1 Inhibitor
    4. Radioligand Therapy Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Prostate Cancer
      2. Neuroendocrine Tumours (NETs)
      3. Others
    5. Radioligand Therapy Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Cancer Treatment Centers
      4. Others
    6. Brazil
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    7. Mexico
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    8. Argentina
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    9. Chile
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    10. Colombia
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
    11. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      3. Market Size & Forecast By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      4. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      5. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
  12. Competitive Landscape
    1. Radioligand Therapy Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Clovis Oncology
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Curium Pharma
    3. Amneal Pharmaceuticals LLC
    4. Novartis AG
    5. Molecular Partners
    6. Pfizer Inc.
    7. Eli Lilly and Company (POINT Biopharma Global Inc.)
    8. Fusion Pharmaceuticals Inc.
    9. Telix Pharmaceuticals
    10. Lantheus Holdings Inc.
    11. Bayer AG
    12. ITM Isotope Technologies Munich SE
    13. Precirix
    14. Radio Medix
    15. Johnson & Johnson Services Inc.
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.